FDA
-
-
-
-
-
-
-
Vaxart Files Definitive Proxy Statement and Mails Letter to Shareholders
-
-
-
-
-
-
-
Vaxart Announces Share Purchase Agreement for up to $25 Million with Lincoln Park Capital
-
-
-
-
-
-
-
Vaxart Reports Additional Phase 1 Data Supporting the Potential Efficacy of its Second-Generation Norovirus Oral Pill Vaccine Candidate
-
-
-
-
-
-
-
Vaxart Publishes Positive, Complete Data from a Phase 2b Challenge Study of its First-Generation Oral Pill Norovirus Vaccine Candidate in Science Translational Medicine
-
-
-
-
-
-
-
Vaxart Announces Clinical Trial Initiation of Norovirus Oral Pill Vaccine Candidate
-
-
-
-
-
-
-
Vaxart Announces Favorable DSMB Review of Sentinel Cohort from COVID-19 Phase 2b Clinical Trial
-
-
-
-
-
-
-
Vaxart (VXRT) Provides Business Update
-
324,250 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

